Abstract
  • ATAGI recommends that a booster dose of the Paediatric Pfizer COVID-19 vaccine (10mcg, ancestral strain) may be given to the following children aged 5 to 11 years who have completed a primary course of vaccination 3 or more months ago:
    • those who are severely immunocompromised
    • those who have a disability with significant or complex health needs
    • those who have complex and/or multiple health conditions that increase the risk of severe COVID-19
  • Currently, Spikevax (Moderna) and the bivalent COVID-19 vaccines are not licensed for use as booster doses in this age group.
  • ATAGI continues to recommend a 3-month interval between a recent confirmed SARS CoV-2 infection and a scheduled dose of COVID-19 vaccine.
  • ATAGI does not recommend that a booster dose of COVID-19 vaccine be given to all children aged 5 to 11 years. There is insufficient evidence of severe disease in otherwise healthy children in this age group who have already received two primary doses of a COVID-19 vaccine. ATAGI continues to recommend that all children aged 5 to 11 years complete a primary vaccine course of 2 doses of COVID-19 vaccine, 8 weeks apart. A third primary dose from 2 months after dose 2 is recommended for those who are severely immunocompromised.
  • Recommendation
  • Western Pacific
  • Australia
  • Children (2-9 years)
  • COVID-19